4D-150
Wet Age-Related Macular Degeneration (wet AMD)
Key Facts
About 4D Molecular Therapeutics
4D Molecular Therapeutics is a visionary gene therapy company leveraging its proprietary Therapeutic Vector Evolution platform to design customized adeno-associated viral (AAV) vectors for specific diseases. The company's most advanced assets target retinal conditions, with 4D-150 showing promising Phase 2 data in wet age-related macular degeneration (AMD) and diabetic macular edema (DME), significantly reducing the need for frequent anti-VEGF injections. With a strategic focus on retina and pulmonology, bolstered by significant partnerships and non-dilutive funding, 4DMT is positioned to advance multiple programs into late-stage development and potentially bring transformative one-time treatments to patients.
View full company profileAbout 4D Molecular Therapeutics
4D Molecular Therapeutics is a visionary gene therapy company leveraging its proprietary Therapeutic Vector Evolution platform to design customized adeno-associated viral (AAV) vectors for specific diseases. The company's most advanced assets target retinal conditions, with 4D-150 showing promising Phase 2 data in wet age-related macular degeneration (AMD) and diabetic macular edema (DME), significantly reducing the need for frequent anti-VEGF injections. With a strategic focus on retina and pulmonology, bolstered by significant partnerships and non-dilutive funding, 4DMT is positioned to advance multiple programs into late-stage development and potentially bring transformative one-time treatments to patients.
View full company profileTherapeutic Areas
Other Wet Age-Related Macular Degeneration (wet AMD) Drugs
| Drug | Company | Phase |
|---|---|---|
| OTX-TKI (axitinib implant) | Ocular Therapeutix | Phase 3 |
| DURAVYU™ (EYP-1901) | EyePoint Pharmaceuticals | Phase 3 |
| Sozinibercept (OPT-302) | Opthea | Phase 3 |
| ONS-5010 / LYTENAVA™ (bevacizumab-vikg) | Outlook Therapeutics | Approved |